Renukaradhya, G.J., Khan, M.A., Shaji, D., and Brutkiewicz, R.R. (2008). Vesicular stomatitis virus matrix protein impairs CDld-mediated antigen presentation through activation of the p38 MAPK pathway. J. Virol. 82, 12535-12542.
Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 7/, 785-797.
Ricklin, D., and Lambris, J.D. (2007). Complement-targeted therapeutics. Nat. Biotechnol 25, 1265-1275.
Ries, S., and Kom, W.M. (2002). ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 86, 5-11.
Rigg, R.J., Chen, J., Dando, J.S., Forestell, S.P., Plavec, I., and BÓHnlein, E. (1996). A novel human amphotropic packaging celi linę: High titer, complement resistance, and improved safety. Virology 218, 290-295.
Roben, P., Moore, J.P., Thali, M., Sodroski, J., Barbas, C.F., and Burton, D.R. (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gpl20 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68,4821-4828.
Roche, S., Bressanelli, S., Rey, F.A., and Gaudin, Y. (2006). Crystal structure of the Iow-pH form of the Vesicular Stomatitis Virus glycoprotein G. Science 313, 187-191.
Roche, S., Rey, F.A., Gaudin, Y., and Bressanelli, S. (2007). Structure of the prefiision form of the Vesicular Stomatitis Virus glycoprotein G. Science 315, 843-848.
Roda, J.M., Parihar, R., Lehman, A., Mani, A., Tridandapani, S., and Carson, W.E. (2006). lnterleukin-21 enhances NK celi activation in response to antibody-coated targets. The Journal of Immunology 777, 120-129.
Rogulski, K.R , Freytag, S.O., Zhang, K., Gilbert, J.D., Paielli, D.L., Kim, J.H., Heise, C.C., and Kim, D.H. (2000). In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193-1196.
Rohde, J., Emschermann, F., Knittler, M., and Rziha, H.-J. (2012). Orf virus interferes with MHC class I surface expression by targeting vesicular transport and Golgi. BMC Vet. Res. 8, 114.
Rollins, S.A., Birks, C.W., Setter, E., Squinto, S.P., and Rother, R.P. (1996). Retroviral vector producer celi killing in human serum is mediated by natural antibody and
212